- CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
- CytoDyn to Host Webcast to Provide Company Update
- May 2024 Letter to Shareholders
- CytoDyn Announces FDA Has Lifted Clinical Hold
- CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
- CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
- CytoDyn Announces Webcast to Provide Company Update
- CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
- November 2023 Letter to Shareholders
- CytoDyn Announces Company Updates and Investment Community Update Webcast
More ▼
Key statistics
As of last trade, Cytodyn Inc (296:STU) traded at 0.157, 27.64% above the 52 week low of 0.123 set on Jul 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.124 |
---|---|
High | 0.157 |
Low | 0.124 |
Bid | 0.131 |
Offer | 0.155 |
Previous close | 0.123 |
Average volume | 72.33k |
---|---|
Shares outstanding | 993.37m |
Free float | 985.39m |
P/E (TTM) | -- |
Market cap | 135.45m USD |
EPS (TTM) | -0.055 USD |
Data delayed at least 15 minutes, as of Jul 02 2024.
More ▼